The part of the Cyclarity update I keep coming back to is the urinary excretion mechanism. The compound they’re using is in the cyclodextrin family, which anyone with a pharmacy background will recognise as a solubilising excipient that’s been around for decades in injectable formulations. The novel part isn’t the molecule itself, it’s using it to scavenge an endogenous oxidised lipid rather than just carry a drug compound through. That shift in application hasn’t been discussed much in the coverage I’ve seen, and I think it matters for how we interpret the pilot. The healthy volunteer data is encouraging in the straightforward sense: no observed adverse effects across doses, cleared renally, no retention. But I’d hold that loosely until the coronary artery disease cohort data arrives. Plaque burden changes the environment considerably. 7-ketocholesterol doesn’t circulate freely in the way a healthy participant’s sample might suggest. It’s embedded in foam cells within established lesions, and whether a cyclodextrin can extract it effectively from that context is genuinely a different question. The other thing worth keeping in mind: statins reduce cholesterol synthesis upstream, they don’t address oxysterols that have already formed. If the Cyclarity mechanism holds, it would be working on a different part of the cascade entirely, less about what arrives at the arterial wall and more about clearing what’s already oxidised in situ. Whether that produces meaningful clinical outcomes is the actual test, and we won’t know until the older CAD population data comes through. I’ve been tracking my own cardiovascular markers more consistently since my father’s bypass last year. The daily check-in flow in CareClinic is honestly the only reason I’ve kept it up long enough to have anything worth showing my GP. Nothing diagnostic, just context. But this trial is one I’ll be following.